SCHEMBL2936718

SCHEMBL2936718

O=C1N(c2ccc(OC(F)(F)F)cc2)C(=O)C2(CC2)N1Cc1cc(N2CCCCC2)nc2ccccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 8/20 0.43
GCGR P47871 2/20 0.42
KDM4E B2RXH2 3/20 0.38
GAA P10253 2/20 0.38
ACHE P22303 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ACP1 P24666 1/20 0.38
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
THRB P10828 1/20 0.37
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37
HPGD P15428 1/20 0.37
ALOX12 P18054 1/20 0.37
IGF1R P08069 1/20 0.37
MCHR2 Q969V1 1/20 0.36
TRPV4 Q9HBA0 1/20 0.36
MGLL Q99685 1/20 0.36
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3739724 0.90 IGF1R (0.47) MCHR1KDM4EGAAACHEL3MBTL1
SCHEMBL2941727 0.87 IGF1R (0.43) MCHR1KDM4EGAAACHEL3MBTL1
SCHEMBL2940739 0.86 GCGR (0.43) MCHR1GCGRIGF1RTRPV4
SCHEMBL2940616 0.86 IGF1R (0.53) MCHR1KDM4EGAAACHEL3MBTL1
SCHEMBL2934900 0.85 GCGR (0.45) MCHR1GCGRL3MBTL1POLBIGF1R
SCHEMBL2938560 0.85 GCGR (0.43) MCHR1GCGRIGF1R
SCHEMBL2938539 0.85 GCGR (0.45) MCHR1GCGRIGF1R
SCHEMBL2941078 0.84 GCGR (0.45) MCHR1GCGRACP1IGF1RTRPV4
SCHEMBL2937182 0.84 GCGR (0.43) MCHR1GCGRIGF1R
SCHEMBL2941211 0.83 GCGR (0.43) MCHR1GCGRACP1IGF1RTRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 MCHR1 4505/4885GCGR 2462/4885KDM4E 1619/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA MCHR1 4236/4885GCGR 2407/4885KDM4E 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.